Isolation of Tumor Antigen-Specific Single-Chain Variable Fragments Using a Chimeric Antigen Receptor Bicistronic Retroviral Vector in a Mammalian Screening Protocol

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges

(2012) Grazyna Lipowska-Bhalla et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

(2011) Michael Kalos   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Lymphocyte Display: A Novel Antibody Selection Platform Based on T Cell Activation

(2009) Vanesa Alonso-Camino et al.   PLoS One

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma

(2008) Eleanor J Cheadle et al.   BRITISH JOURNAL OF HAEMATOLOGY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE